mirabegron + fesoterodine

mirabegron + fesoterodine is a combination therapy used for overactive bladder (OAB). Mirabegron acts as a **β3 adrenoceptor agonist**, relaxing detrusor smooth muscle by activating adenylyl cyclase and increasing bladder capacity. Fesoterodine is a **nonselective muscarinic receptor antagonist** (prodrug for 5-hydroxymethyl tolterodine), blocking M2 and M3 receptors, thus inhibiting acetylcholine-mediated bladder contractions. The combination leverages **complementary mechanisms** for potentially synergistic improvement in bladder storage symptoms. Animal studies show that the combination increases bladder capacity more than either drug alone, with additive relaxant effects on the bladder.

Brand names

Myrbetriq + Toviaz

Other names

mirabegron + fesoterodine